A Phase I Study of Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

March 31, 2013

Study Completion Date

April 30, 2013

Conditions

Type 2 Diabetes

Interventions

DRUG

PEX168

A injection administered subcutaneously

Trial Locations (1)

People's Liberation Army General Hospital of Chengdu Military Region, Chengdu

All Listed Sponsors

collaborator

People's Liberation Army General Hospital of Chengdu Military Region

UNKNOWN

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT01965496 - A Phase I Study of Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes | Biotech Hunter | Biotech Hunter